[Chemo-radiotherapy combination in small cell bronchial carcinomas. Limitations and results in 109 patients treated with an alternating protocol].
One hundred and nine patients with limited small cell lung carcinoma were entered in a phase II study alternating six cycles of combination chemotherapy and three courses of mediastinal radiotherapy. Chemotherapy consisted of doxorubicin 40 mg/m2 day 1, etoposide 75 mg/m2 days 1, 2, 3, cyclophosphamide 300 mg/m2 days 3, 4, 5, 6, and methotrexate 400 mg/m2 day 2 (+folinic acid rescue) or cisplatin 100 mg/m2 day 2. The total mediastinal radiation dose was 45 or 55 Gy. A 6 to 8 cycle maintenance chemotherapy followed this induction protocol. The complete remission rate at the end of the induction therapy was 79%. The local recurrence rate was 25% and the distant metastases rate was 52%. Median survival is 17.2 +/- 1.2 months and survival rate at 3 years is 26%. Lethal toxicity occurred in 3% of patients during induction therapy, and long term survivors are being evaluated. Our results justify further investigations with this alternating schedule.
Le Chevalier
T
T
Institut Gustave-Roussy, Villejuif, France.
Arriagada
R
R
Baldeyrou
P
P
de Cremoux
H
H
Ruffié
P
P
Martin
M
M
Cerrina
M L
ML
de Thé
G
G
Sancho-Garnier
H
H
Hayat
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011829:Radiation Dosage; D013997:Time Factors
Association chimio-radiothérapique dans les carcinomes bronchiques à petites cellules. Limites et résultats chez 109 malades traites avec un schéma d'alternance.